
Opinion|Videos|May 16, 2024
Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care
Medical professionals share insights on treatment considerations and patient selection for bispecific antibody therapy and the process for referring patients to other institutions for care.
Advertisement
Episodes in this series

Advertisement
Related to this article

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
3
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5




